Scholarlink

Aim <p>Sepsis-induced cardiomyopathy (SICM) is a transient cardiac dysfunction that occurs in a substantial proportion of patients with sepsis and is associated with poor prognosis. However, preventive strategies remain limited. This study aimed to assess whether baseline use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) compared to dipeptidyl peptidase-4 inhibitors (DPP4is) is associated with a reduced risk of SICM in patients with type 2 diabetes mellitus (T2D) and sepsis.</p> Methods <p>Using the TriNetX global health research network, we conducted a retrospective cohort study including adult patients with T2D and infection who were prescribed either SGLT2is or DPP4is within three months before infection. Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was SICM within 30 days; secondary outcomes included 1-year all-cause mortality, hospitalization, and major adverse cardiovascular events (MACEs).</p> Results <p>After 1:1 PSM for demographics, comorbidities, and medications, 73,069 patients were included in each group. SGLT2is use was associated with a significantly lower risk of SICM (hazard ratio [HR], 0.78; 95% CI, 0.71–0.86), all-cause mortality (HR, 0.58; 95% CI, 0.55–0.62), hospitalization (HR, 0.83; 95% CI, 0.79–0.87), and MACEs (HR, 0.86; 95% CI, 0.80–0.93), all <i>P</i> &lt; .001, compared to DPP4is therapy. Subgroup analyses and negative control outcomes supported the robustness of the findings.</p> Conclusions <p>Among patients with T2D and sepsis, SGLT2is were associated with a lower risk of SICM and improved long-term cardiovascular outcomes, compared to DPP4is therapy. These results support further prospective studies to validate the role of SGLT2is in preventing SICM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Jheng-Yan Wu,
  • Kuan-Jui Tseng,
  • Chia-Li Kao,
  • Kuo-Chuan Hung,
  • Tsung Yu,
  • Yu-Min Lin

摘要

Aim

Sepsis-induced cardiomyopathy (SICM) is a transient cardiac dysfunction that occurs in a substantial proportion of patients with sepsis and is associated with poor prognosis. However, preventive strategies remain limited. This study aimed to assess whether baseline use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) compared to dipeptidyl peptidase-4 inhibitors (DPP4is) is associated with a reduced risk of SICM in patients with type 2 diabetes mellitus (T2D) and sepsis.

Methods

Using the TriNetX global health research network, we conducted a retrospective cohort study including adult patients with T2D and infection who were prescribed either SGLT2is or DPP4is within three months before infection. Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was SICM within 30 days; secondary outcomes included 1-year all-cause mortality, hospitalization, and major adverse cardiovascular events (MACEs).

Results

After 1:1 PSM for demographics, comorbidities, and medications, 73,069 patients were included in each group. SGLT2is use was associated with a significantly lower risk of SICM (hazard ratio [HR], 0.78; 95% CI, 0.71–0.86), all-cause mortality (HR, 0.58; 95% CI, 0.55–0.62), hospitalization (HR, 0.83; 95% CI, 0.79–0.87), and MACEs (HR, 0.86; 95% CI, 0.80–0.93), all P < .001, compared to DPP4is therapy. Subgroup analyses and negative control outcomes supported the robustness of the findings.

Conclusions

Among patients with T2D and sepsis, SGLT2is were associated with a lower risk of SICM and improved long-term cardiovascular outcomes, compared to DPP4is therapy. These results support further prospective studies to validate the role of SGLT2is in preventing SICM.